Outgoing Lung Team - a Cross-sectorial Intervention in Patients With COPD

January 19, 2021 updated by: University of Aarhus

Outgoing Lung Team - a Cross-sectorial and Preventive Intervention in Patients at Risk of Hospitalisation Due to Exacerbation of COPD

This study examines the effects of the work of an outgoing lung team in the Municipality of Aarhus, Denmark to patients with COPD (Chronic obstructive pulmonary disease) at risk of exacerbation of COPD.

The outgoing lung team is a cross-sectorial team of nurses and doctors from Department of Respiratory Diseases and Allergy at Aarhus University Hospital and nurses from the Acute Team in the Municipality of Aarhus.

The work of the outgoing lung team takes place in the patient's home and involves the following:

  • The outgoing lung team teaches the patients, relatives and primary care staff about symptoms, treatments and instructions related to COPD.
  • The patients, relatives and primary care staff can contact the outgoing lung team by telephone day and night.
  • The outgoing lung team initiates appropriate treatment by telephone or a home visit in consultation with a doctor.
  • The patients report symptoms and measurements to the outgoing lung team using telemedicine solutions (AmbuFlex).
  • The outgoing lung team initiates acute consultations at Department of Respiratory Diseases and Allergy based on patient reported outcomes, home visit or telephone call.

Half of the participants are affiliated to the outgoing lung team, while the other half are not, and continue their usual practice by contacting the general practitioners in case of exacerbation of COPD.

The main hypothesis of the project is that outgoing lung team has a positive impact on continuity of care across sectors in the Danish healthcare system for patients with COPD. More specifically the hypotheses are:

  1. Affiliation to the outgoing lung team reduces admissions, readmissions, length of hospital stay and outpatient consultations.
  2. Affiliation to the outgoing lung team reduces anxiety and depression and increases patient involvement, and improves patients' health status and self-efficacy.
  3. Affiliation to the outgoing lung team increases patients' level of health literacy.

Study Overview

Status

Completed

Conditions

Detailed Description

Background

Worldwide, COPD is a major cause of morbidity and mortality and is currently the fourth leading cause of death and projected to be the third leading cause of death by 2020. In 2010, the estimated number of COPD cases worldwide was 384 million with a prevalence of 11% (95% confidence interval: 8,4%-15,0%).

COPD is characterised by airway obstruction due to inflammation and destruction of lung tissue. The disease causes breathlessness, cough, mucus and frequent respiratory infections and leads to decreased lung function. COPD often affects patients' quality of life negatively as many experience anxiety because of breathlessness. Breathing difficulties reduce patients' level of activity and can lead to social isolation. In Denmark, it is estimated that 320,000 Danes have COPD. In 2018, the number of admissions due to COPD in Denmark was 34,961 with a readmission rate (new hospitalisation within 30 days after the last hospitalisation) of 19% and a 30-day mortality rate of 11%.There were 49,424 outpatient visits due to COPD in Denmark in 2018, and approximately 5,500 annual deaths where COPD is the direct or contributory cause.

It is estimated that the total annual treatment costs for patients with COPD in Denmark amount to approximately DKK 3,345 billion, and most of these costs are related to acute admissions.

Previous research shows that patients with COPD experience not being offered the same quality of treatment as other chronic patients. Furthermore, patients with COPD report that they are not taken seriously by healthcare professionals, which induces insecurity.

As patients with COPD constitute a large group in both the primary and secondary care, we intend to improve the collaboration between the two sectors based on patients´ preferences. The patients emphasized the importance of having the possibility to contact a specialised respiratory nurse 24-7. Patients reported that they preferred education to take place close to home, as transportation to hospital or the community support centre for older people were both mentally and physically straining.

Research showed that home visits by a respiratory nurse from the hospital reduce admissions and readmissions. Furthermore, research showed that home visits by the nurses in primary care also decrease admissions and readmissions. Some of the interventions were treatment at home and some comprised education regarding management of acute exacerbations and observations of symptoms, inhalation, smoking cessation, nutrition etc.

The interventions consisted of collaboration between primary care nurses and the general practitioners (GPs), and in other interventions primary care nurses were supervised by the specialist respiratory nurses at the hospital often by phone or at joint visits in the patients' home.

Home visits after discharge paid by a respiratory nurse and interdisciplinary cooperation showed that patients with COPD felt safe and comforted and were motivated to make changes to achieve better health.

However, other studies showed that education improved patients' knowledge but it did not prevent readmissions.

So far, no studies have been performed investigating cross-sectorial collaboration with a lung team and preventive intervention in patients at risk of hospitalisation due to exacerbation of COPD.

Department of Respiratory Diseases and Allergy at Aarhus University Hospital, Denmark and the Acute Team in the Municipality of Aarhus, Denmark started a pilot project from September 2015 until October 2016. The project concerned establishment of an outgoing lung team comprised by a team of nurses from both the primary and secondary sector. The aim was to increase knowledge and competences among patients, relatives and staff in relation to care and treatment, to reduce the rate of hospitalisation and readmission and to evaluate the impact of the outgoing lung team on participants' health status. The pilot project had several limitations 1) It was only possible to evaluate the effect of the outgoing lung team during six months. We were thus unable to evaluate variety over the year which may have impacted on the number of hospitalisations, readmissions and episodes of exacerbation. 2) The pilot project had no control group. We thus wanted to qualify the project by using a randomised controlled trial design.

We also wanted to examine the impact of the outgoing lung team on the level of patient involvement, anxiety, depression and health literacy. Health literacy is linked to literacy and entails people's knowledge, motivation and competences to access, understand, appraise and apply health information in order to make judgements and take decisions in everyday life concerning health care, disease prevention and health promotion to maintain or improve quality of life during the life course. Studies show that patients with COPD have lower levels of health literacy compared with people with no chronic diseases. Increasing the level of health literacy in this population would thus be relevant.

Furthermore, we wished to examine the effect of the outgoing lung team on patients' health status, their experiences of being affiliated to the outgoing lung team as well as their self-efficacy.

Objective

The aim is to examine the effects of the work of an outgoing lung team in the Municipality of Aarhus to patients with COPD at risk of exacerbation of COPD.

Hypothesis

The main hypothesis is that outgoing lung team has a positive impact on continuity of care across sectors in the Danish healthcare system for patients with COPD. To examine this we have three subhypotheses.

  1. Affiliation to the outgoing lung team reduces admissions, readmissions, length of hospital stay and outpatient consultations.
  2. Affiliation to the outgoing lung team reduces anxiety and depression and increases patient involvement, and improves patients' health status and self-efficacy.
  3. Affiliation to the outgoing lung team increases patients' level of health literacy.

Materials and method

Setting and location

The outgoing lung team is a cross-sectorial team of nurses and doctors from Department of Respiratory Diseases and Allergy at Aarhus University Hospital in Denmark and nurses from the Acute Team in the Municipality of Aarhus in Denmark. The outgoing lung team intends to preserve, detect, diagnose and treat patients with an exacerbation of COPD. The outgoing lung team is physically located at the office of the Acute Team; in this office knowledge sharing and upgrading of skills take place.

The work of the outgoing lung team takes place in the patient's home and involves the following:

  • The outgoing lung team teaches the patients, relatives and primary care staff about symptoms, treatments and instructions related to COPD.
  • The patients, relatives and primary care staff can contact the outgoing lung team by telephone day and night.
  • The patients report symptoms and measurements to the outgoing lung team using telemedicine solutions, also known as patient reported outcomes.
  • The outgoing lung team initiates appropriate treatment by telephone or a home visit. The outgoing lung team always consults a doctor from the Department of Respiratory Diseases and Allergy before initiating treatment.
  • The outgoing lung team initiates acute consultations at Department of Respiratory Diseases and Allergy based on patient reported outcomes, home visit or telephone call.

Doctors at Department of Respiratory Diseases and Allergy are responsible for the medical treatment as long as the patient participates in the project. The GPs in the Municipality of Aarhus have agreed to this. The GPs can refer patients to the project and some of them participate in a project advisory board.

Study design

The project is designed as a mixed-method study based on a randomised controlled trial with an intervention group connected to the outgoing lung team and a control group attending the standard pathway programme at Department of Respiratory Diseases and Allergy at Aarhus University Hospital, Denmark.

Sample size

Based on a retrospective sample of admissions related to COPD in the period from February to August 2014-2016, an expected decrease in length of hospital stay can be calculated as the outgoing lung team was introduced in 2016. Mean number of admission days in the retrospective sample followed a normal distribution after logarithmic transformation, as assessed by histograms. Number of admission days (geometric mean) was 5.69 (95% CI: 2.78-11.6) in 2014-2015, and 4.50 (2.62-7.76) in 2016. Based on these numbers, the power calculation resulted in inclusion of 64 patients in the intervention and control group, respectively to be able to demonstrate a significant difference with a power of 80% and at a significance level of 5%.

In the pilot project the withdrawal was 23%. With an estimated withdrawal at 23% we will need 83 patients in each group.

Missing data

After one year, we contact all participants and arrange a plan for answering the questionnaires. The missing data, will be registered in Stata and mentioned in the study.

Analysis

Data will be statistically analysed both descriptive and analytically. Correlations and significant factors as lung function, gender, age etc. will be examined and significant differences between the two groups (intervention group and control group) in the studies which may have an impact on results.

To identify predictors of the impact on the dependent variable we will use bivariate x 2 test and calculation of odds ratios, multiple logistic regression and logarithmic data. The statistical analysis will be performed in Stata 16.

Qualitative data from the interviews in will be transcribed and analysed based on meaning condensation analysis.

Ethics

Ethical approval will be obtained from Central Denmark Region Committees on Health Research Ethics and approval of data archives and storage will be obtained from the Danish Data Protection Agency in Central Denmark Region in RedCap. All collected personal data will be anonymised, processed, analysed and stored in accordance with the Danish Data Protection Agency. All participants will receive oral and written information. Patients who agree to participate will provide written informed consent.

Study Type

Interventional

Enrollment (Actual)

144

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Aarhus N, Denmark, 8200
        • Department of Respiratory Diseases and Allergy

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 100 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Citizens of the Municipality of Aarhus
  2. FEV1 <50% predicted and at least one hospitalisation due to COPD and/or two tablet-treated episodes of exacerbation (prednisolone and /or antibiotics) within the last year
  3. Special needs due to anxiety, dyspnea etc. that cause frequent hospitalisations

Exclusion Criteria:

  1. Participation in the pilot project
  2. Inability to speak, read and understand Danish
  3. Severe cognitive disability and thus inability to understand and fill in questionnaires (e.g. dementia)
  4. No wish to participate in the project

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: SUPPORTIVE_CARE
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
OTHER: Intervention group

Affiliation with outgoing lung team

  • Instructions and teaching by the outgoing lung team.
  • Needs-based consultation at Dept. of Respiratory Diseases and Allergy.
  • Contact to the outgoing lung team in case of exacerbation of COPD.

The work of the outgoing lung team takes place in the patient's home and involves the following:

  • The outgoing lung team teaches the patients, relatives and primary care staff about symptoms, treatments and instructions related to COPD.
  • The patients, relatives and primary care staff can contact the outgoing lung team by telephone day and night.
  • The patients report symptoms and measurements to the outgoing lung team using telemedicine as patient reported outcomes.
  • The outgoing lung team initiates appropriate treatment by telephone or a home visit. The outgoing lung team always consults a doctor from the Department of Respiratory Diseases and Allergy before initiating treatment.
  • The outgoing lung team initiates acute consultations at Department of Respiratory Diseases and Allergy based on patient reported outcomes, home visit or telephone call.
NO_INTERVENTION: Control group

The usual practice

  • Scheduled consultations at Dept. of Respiratory Diseases and Allergy.
  • Contact to GP/doctor on call in case of exacerbation of COPD.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in admissions and re-admissions.
Time Frame: One year. From date of randomization and after one year.
Data from the patients records.
One year. From date of randomization and after one year.
Length of hospitalisation related to COPD.
Time Frame: One year. From date of randomization and after one year
Data from the patients records.
One year. From date of randomization and after one year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of outpatient consultations related COPD.
Time Frame: One year. From date of randomization and after one year.
Data from the patients records.
One year. From date of randomization and after one year.
Measure level of patient involvement
Time Frame: One year. From date of randomization and after one year.
Self reported level of patient involvement. The questionnaire PACIC (Patient Assessment of Chronic Illness Care) comprised of 20-items. Each item is scored "Never", "Usually not", "Sometimes" "Usually" or "Always"
One year. From date of randomization and after one year.
Change in health status
Time Frame: One year. From date of randomization and after one year.
Self reported health status. The questionnaire CAT (COPD Assessment Test) comprised of 8 items. Each item is scored 0-5 (O = never, and 5 = always)
One year. From date of randomization and after one year.
Change in quality of life
Time Frame: One year. From date of randomization and after one year.
Self reported data based on the questionaire EQ-5D-3L (Euro-quality of life group- 5 dimensions- 3 level). Each item is scores 1-3 (1= No problems, 3= Many problems)
One year. From date of randomization and after one year.
Change in anxiety and depression
Time Frame: One year. From date of randomization and after one year.
Self reported data based on the questionaire HADS (Hospital Anxiety and Depression Scale). It consists of 14 items. Each items is scored 1-4 (1 = Most of the time/ definitely to 4= very rare/ definitely not)
One year. From date of randomization and after one year.
Change in level of health literacy
Time Frame: One year. From date of randomization and after one year.
Self reported data based on the questionaire HLQ (Health Literacy Questionnaire). It comprises of 9 domains. In this study we use 3 domains and it consists of 15 items. 1 domain comprised of 5 items, and each item is scored from "totally not agree" to " not agree", "agree" and "totally agree". The two other domains comprises in total of 10 domains, where each item is scored from "Always difficult", "Often difficult", "Sometimes difficult", "Often easy" and "Always easy".
One year. From date of randomization and after one year.
Change in self-efficacy
Time Frame: One year. From date of randomization and after one year.
Self reported data based on the questionaire CSES (COPD Self-Efficacy Scale). It comprises of 34 items, and each item is scores from "very sure", "pretty Sure", "partly sure", "not very sure" and definitely not sure"
One year. From date of randomization and after one year.
Experiences of affiliation with the outgoing lung team.
Time Frame: One time after, they have been affiliated with the outgoing lung team for at least 7 month.
Interviews with patients who have been affiliated with the outgoing lung team.
One time after, they have been affiliated with the outgoing lung team for at least 7 month.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Birgit R Iversen, Ph.d.-stud., Department of Respiratory Diseases and Allergy, Aarhus University Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

September 25, 2017

Primary Completion (ACTUAL)

March 31, 2020

Study Completion (ACTUAL)

November 30, 2020

Study Registration Dates

First Submitted

October 7, 2019

First Submitted That Met QC Criteria

October 7, 2019

First Posted (ACTUAL)

October 8, 2019

Study Record Updates

Last Update Posted (ACTUAL)

January 22, 2021

Last Update Submitted That Met QC Criteria

January 19, 2021

Last Verified

July 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COPD

Clinical Trials on Affiliation with the outgoing lung team

3
Subscribe